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Abstract
Background: We have previously reported a high incidence of colorectal cancer (CRC) in carriers of pathogenic
MLH1 variants (path_MLH1) despite follow-up with colonoscopy including polypectomy.
Methods: The cohort included Finnish carriers enrolled in 3-yearly colonoscopy (n = 505; 4625 observation years)
and carriers from other countries enrolled in colonoscopy 2-yearly or more frequently (n = 439; 3299 observation
years). We examined whether the longer interval between colonoscopies in Finland could explain the high
incidence of CRC and whether disease expression correlated with differences in population CRC incidence.
Results: Cumulative CRC incidences in carriers of path_MLH1 at 70-years of age were 41% for males and 36% for
females in the Finnish series and 58% and 55% in the non-Finnish series, respectively (p > 0.05). Mean time from last
colonoscopy to CRC was 32.7 months in the Finnish compared to 31.0 months in the non-Finnish (p > 0.05) and
was therefore unaffected by the recommended colonoscopy interval. Differences in population incidence of CRC
could not explain the lower point estimates for CRC in the Finnish series. Ten-year overall survival after CRC was
similar for the Finnish and non-Finnish series (88% and 91%, respectively; p > 0.05).
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Conclusions: The hypothesis that the high incidence of CRC in path_MLH1 carriers was caused by a higher
incidence in the Finnish series was not valid. We discuss whether the results were influenced by methodological
shortcomings in our study or whether the assumption that a shorter interval between colonoscopies leads to a
lower CRC incidence may be wrong. This second possibility is intriguing, because it suggests the dogma that CRC
in path_MLH1 carriers develops from polyps that can be detected at colonoscopy and removed to prevent CRC
may be erroneous. In view of the excellent 10-year overall survival in the Finnish and non-Finnish series we remain
strong advocates of current surveillance practices for those with LS pending studies that will inform new
recommendations on the best surveillance interval.
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Background
Lynch syndrome (LS) is an autosomal dominantly inherited
cancer syndrome predisposing to colorectal cancer (CRC)
and several extra-colonic malignancies [1]. It is the most
common hereditary cause of CRC, accounting for about 3%
of the disease. LS is caused by constitutional pathogenic
variants of any of four DNA mismatch repair (MMR) genes
(MLH1, MSH2, PMS2 and MSH6) or by a deletion in the
EPCAM gene which leads to MSH2 inactivation. In muta-
tion carriers, a somatic mutation affecting the second allele
leads to defective MMR activity.
Based on the international Prospective Lynch Syndrome
Database (PLSD) we have demonstrated that stringent
current screening guidelines do not protect fully against the
development of colorectal cancer (CRC) in path_MMR car-
riers. This observation is despite undertaking colonoscopies
with polypectomies every 3 years or even more frequently
[2]. This finding is in contrast to the declared goal of the
guidelines [1] that follow-up by colonoscopy and polypect-
omy aims to prevent CRC – an outcome that we expected
to be true when issuing these guidelines. Nonetheless, LS
patients undergoing surveillance often survive their first can-
cer and many develop subsequent cancers, again with a good
prognosis, albeit a CRC mortality rate of approximately 10%.
There are many possible reasons why CRC continued to
occur in our previously reported series despite follow-up
with colonoscopy and polypectomy. These reasons include
too great an interval between colonoscopies (Table 1). A
high rate of interval CRCs in LS patients having surveillance
with screening intervals of over 3 years previously prompted
those involved in revising guidelines to recommend shorter
surveillance intervals [1, 3–11]. This change was based upon
the assumption that a major cause of interval cancers was a
fast transition from visible adenomatous polyp to cancer as
a consequence of the increased mutation rate associated
with MMR deficiency [12]. A 3-year interval between colon-
oscopies has been shown to reduce the CRC incidence and
mortality in LS in a comparative prospective study [3].
However, previous relevant studies [3–7, 13–18] (summa-
rized in Table 2) have provided no definite empirically
observed evidence to support what interval between
colonoscopies might best prevent CRC in LS, and how
protective such an intervention might be.
Among LS patients in our previous reports from
PLSD, path_MLH1 carriers had the highest incidence of
CRC despite surveillance colonoscopy, making them the
best cohort to examine why CRC continued to occur.
The first hypothesis considered was that the large num-
ber of carriers reported in PLSD who were from Finland
represented a potential confounder. The high overall
incidence of CRC observed in path_MLH1 carriers in
PLSD might have arisen because Finland, unlike other
countries, had not shortened the recommended interval
between colonoscopies from the original 3 year interval
advocated many years ago.
Here we report whether or not the high CRC incidence in
path_MLH1 carriers despite colonoscopy surveillance was
caused by a high incidence in Finland and investigate time
to CRC cancer since last colonoscopy and overall survival.
Methods
The Prospective Lynch syndrome database
PLSD contains data stored as an Oracle© relational
database. Details on data storage and manipulation have
been described in detail earlier [2]. Patients who were
subject to prospective follow-up including colonoscopy
were reported from LS registries in 13 centers in Europe
and Australia. In some cases screening for early detec-
tion of endometrial and ovarian cancer were also imple-
mented. Details on the guidelines followed at each
contributing center are given in Table 1.
Study design
The design was a prospective, case-based, open observational
study of path_MLH1 carriers subjected to colonoscopy com-
paring two groups with different recommended intervals be-
tween colonoscopies. The prospective observations recorded
included follow-up from first prospectively planned and car-
ried out colonoscopy onwards. Patients with any cancer prior
to, or at the age of first colonoscopy (prevalent cancers) were
excluded, as were subjects with less than 1 year of prospect-
ive observation. The following observations were used: age at
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first colonoscopy, gender, age at last observation, months
from last completed colonoscopy to diagnosis of CRC, age at
any cancer together with the ICD diagnosis of the cancer,
and age at death.
Inclusion criteria
All patients included had been subject to prospective
follow-up with colonoscopy because of their increased
risk for CRC. All were confirmed carriers of
path_MLH1 variants by genetic testing. All path_MLH1
variants were checked against the LOVD database
(http://chromium.lovd.nl/LOVD2/colon_cancer/). Please see
our previous report for a more detailed description of
inclusion criteria [2].
Time between colonoscopies in the different centers
All subjects were offered planned regular surveillance
colonoscopy and polyp removal according to the guide-
lines followed at each reporting center (Table 1). The
recommended colonoscopy interval in the Finnish na-
tional registry protocol was 3 years throughout the study
period. From 1997 onwards, all the other centers recom-
mended surveillance intervals of 2 years or less. Thus,
only observations from 1997 onwards were included in
the present study. Each center kept track of their activities
through medical files and/or research registries, and all
were able to contribute complete reports for all patients
included with no missing values. Whilst these methods do
not conform to the stringency of a clinical trial they none-
theless represent the best that can be achieved by a collab-
orative group of highly interested expert clinicians
working in diverse health service systems.
Surveillance for extra-colonic cancers
Patients in the contributing centers were informed of
general cancer awareness but the surveillance for extra-
colonic cancers varied across the centers (Table 1).
Table 1 National surveillance protocols for colorectal and endometrial cancer
Center Series
cencored
Colonoscopy Gynecological examination Reference no. and
additional details
Interval From-to Interval From-to Modalities in
addition to clinical
examination
Finland 2014 3 years 1985–2014 1 year 1995-2014 EB, ultrasound,
CA12-5
[3, 4, 8]
Denmark 2014 2 years 1991–2014 2 years 1991-2014 US [9]
Germany 2014 1 year 1995–2014 1 year 1995-2014 US [10, 17]
Italy 2013 1-2 years (1 year
when age > 40 years; adenoma)
1990–2013 2 years
(1 years when age > 35 yrs.)
1990-2013 US, Pap smear [11]
UK (Manchester) 2014 2 years 1994–2014 1 year 1990-2014 Hysteroscopy, US,
CA12-5
[6]
Sweden 2014 2 years 1990–2000 1 year 1992-2014 US, CA 12-5.
Some patients: EB
[25, 26]
18 months 2000–2014
Australia 2014 1 year 1990–2014 1 year 1990-2005 US, EB, CA12-5 https://www.nhmrc.gov.au/
_files_nhmrc/publications/
attachments/cp106_0.pdf
https://www.nhmrc.gov.au/
_files_nhmrc/publications/
attachments/cp106_0.pdf
2005-2014 Risk reducing
surgery only
Spain 2013 1-2 years (1 year
when age > 40 years)
1999–2013 1 year 1999-2013 US Unpublished
The Netherlands 2013 2-3 years 1987–1996 1-2 years 1994-2005 US [7]
2 years 1997–2013 1-2 years 2005-2013 US, EB
UK (Cardiff) 2013 3 years 1991–1994 1 year 1998-2010 US, CA12-5
(3 or 4 monthly)
Unpublished
Colonoscopy 96%
compliance with interval.
2 years 1994–2013 Gyn: only 27% of
eligible women had gyn.
Cancer screening.
Since 2010 not systematic.
UK (Newcastle) 2014 2 years 1995–2014 No fixed Unpublished
Norway 2013 3 years 1989–1996 2 years 1989-2013 US, CA12-5 [5]
2 years (one year when adenoma) 1996–2013
US Transvaginal ultrasound
EB Endometrial biopsy
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Cancer treatment
All cancers were treated according to local standards.
Treatment modalities were not considered.
Events scored
All infiltrating CRCs were scored using the first three
positions in the ICD-9 system. Age at each cancer was
recorded. Age at death was recorded.
Annual and cumulative incidence rates
Each patient was observed from age at inclusion to age
at last observation or first cancer. For each patient, the
number of years observed in each five-year group from
25 years of age onwards was counted. All first cancers
were scored according to the age at diagnosis. Annual
incidence rates (AIR) for age groups were calculated by
dividing the number of cancers observed by the total
number of observation years. Each patient was counted
once only, irrespective of how many synchronous can-
cers the patient might have had as first cancers. Later
cancers were not considered. Cumulative incidence,
denoted by Q, was computed starting at age 25, assuming
zero incidence before age 25, using the formula
Q(age) = Q(age-1) + [1-Q(age-1)]·AIR(age) where AIR(age)
is the annual incidence for the corresponding 5 year inter-
val. The hazard rate H = −ln[1-AIR] was used with stand-
ard error estimated as SEH = SEAIR/(1-AIR). The standard
error, denoted by SEQ, was computed in two steps and
95% confidence intervals were estimated. Follow-up contin-
ued after the occurrence of first cancers, and all patients
were either reported to be alive or validated to be alive in a
population register when censored. See our previous report
[2] for a more detailed description of these methods. Differ-
ences in time-to-events were also calculated by the Kaplan-
Meier algorithm and Mantel-Cox p-values when
appropriate.
Survival
Crude survival was calculated by the Kaplan-Meier algo-
rithm and Mantel-Cox p-values as time from first cancer
to last observation/death. Cancer stages at diagnosis and
causes of death were not considered in this report.
Table 2 Studies assessing the effect of colonoscopy surveillance interval in LS
Study Ref. Subjects Inclusion criteria Setting CS Interval Findings
Järvinen, 2000 [3] 252 Amsterdam criteria
and LS, gene
tested
Prospective, controlled
non-randomized trial
3 years CRC reduced 62% in 15 years compared to
not screened.Mortality reduced 65% vs. no
CS surveillance. Adherence 93%.
Dove-Edwin, 2005 [13] 290 Amsterdam criteria Retrospective 3 years Estimated 72% reduction of CRC mortality
when screened. Adherence not reported.
Mecklin, 2007 [4] 420 LS, gene tested Prospective, observational 3 years Estimated risk for CRC 22% for women and
35% for men before age 60. No increase in
CRC mortality compared to non-carriers.
Adherence 98%.
Järvinen, 2009 [14] 242 LS, gene tested Prospective, controlled
non-randomized observational
3 years CRC incidence 12.4% in 11·5 years, no
increase in CRC mortality compared to
non-carriers. Adherence 96%.
De vos tot Nederveen
Cappel, 2002
[15] 857 Amsterdam criteria
or gene tested
Retrospective 2-3 years 10.5% cumulative CRC risk in 10 years under
surveillance. Lower tumor stage if CS
interval < 2 years.
Stormorken, 2007 [5] 601 Amsterdam criteria
or gene tested
Prospective, observational 2-3 years CRC incidence of LS carriers not increased
compared to non-carriers.
Adherence not reported.
Newton, 2015 [6] 227 LS, gene tested Retrospective 2-3 years CRC incidence 25% at age 70.
Adherence 87%.
Stupart, 2009 [16] 178 LS, MLH1 mutation Prospective, controlled
non-randomized observational
1-2 years CRC incidence 11% in 5 years compared
to 27% if no surveillance.
Adherence not reported.
Vasen, 2010 [7] 745 LS, gene tested Retrospective 1-2 years CRC cumulative risk 6% in 7·2 years.
Adherence not reported.
Engel, 2010 [17] 622 LS, gene tested Prospective, controlled
non-randomized observational
1-2 years CRC cumulative risk at age 60 23%, early
stages. Adherence 81% to 15 months.
Stuckless, 2012 [18] 152 LS, MSH2 mutation Retrospective 1-2 years CRC reduced 71% in 10 years, interval
cancers 27% in males and 15% in females.
Adherence 44%.
LS Lynch syndrome
CRC colorectal cancer
CS colonoscopy
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Results
There were 7924 observation years in the final analysis
from 430 males and 514 females (n = 944). The Finnish
series included 4625 and the non-Finnish series 3299
observation years after first colonoscopies. Ages at inclu-
sion were similar for both series (35.2 years and
36.1 years, respectively; p > 0.05). Baseline characteristics
of the study population and the classification of
path_MLH1 variants are presented in Table 3.
Classification of path_MLH1 variants
Seven hundred and six (75%) of the patients carried
path_MLH1 variants found in LOVD, and 238 of vari-
ants (25%) were not found in LOVD. Among the 706
found in LOVD, 691 (98%) were pathogenic (class 5)
and 15 (2%) were probably pathogenic (class 4). Among
the 505 in the Finnish series 406 (80%) and four (0.7%)
had class 5 and class 4 variants, Among the non-Finnish
series 285 (65%) had class 5 and 11 (2.5%) class 4
variants in LOVD, Among the 238 variants not reported
to LOVD 95 were detected in the Finnish series and 143
in the non-Finnish series. All of them were eventually
classified as class 5 and 4 based on the combined assess-
ment of two of the co-authors (IF, JS) following the
updated InSight rules [19].
Cumulative incidences of cancers
A total of 101 CRCs and 83 extra-colonic cancers were di-
agnosed during the follow-up period. Despite less frequent
colonoscopy, the cumulative incidences of CRC were mod-
estly lower for the Finnish series compared to the non-
Finnish series in all age groups (39.2%; 95% confidence
interval 29.4–48.9 vs 53%; 39.6–68) but not significantly so.
Regarding extra-colonic cancers, similar observations were
made (39.7%; 28.2–51.2 vs 57.2%; 41–73.5, respectively).
The cumulative incidence rates categorized by 10-year in-
tervals from age 25 are shown in Table 4 and Fig. 1a and b.
Additional file 1: Table S1 presents the annual incidence
rates of cancers categorized by five-year intervals from 25
to 70 years.
The similar age of inclusion allowed us to make com-
parisons of time from inclusion to diagnosis of CRC
using the Kaplan-Meier algorithm. In the Finnish series,
3 and 11% of carriers were diagnosed with CRC after 5
and 10 years of follow-up, respectively, compared to 5
and 14%, respectively in the non-Finnish series
(p > 0.05). The differences were modestly larger in males
than in females (Fig. 1c). The percentages of carriers
developing extra-colonic cancers were also similar: 3
and 9% at 5 and 10 years after inclusion in the Finnish
series compared to 3 and 11% in the non-Finnish series
(p > 0.05). In sum, none of the differences were signifi-
cant and all point estimates were similar or lower in the
Finnish series.
Correlation with population incidence of CRC
Next, we explored the correlation between observed
CRC incidences in path_MLH1 LS patients and the cor-
responding population incidences of CRC. The relative
incidence of CRC in the Finnish population compared to
the other countries was 0.80 [the age-standardized inci-
dence rate in Finland was 35.0 per 100,000 versus a
mean of 43.6 per 100,000 for the other reporting coun-
tries (http://eco.iarc.fr/EUCAN/; downloaded October
2015)]. By comparison, the observed ratio of cumulative
risk for CRC at 70 years in the Finnish series of
path_MLH1 carriers compared to the others was similar:
0.72 (39.2% in the Finnish series versus the average of
54.8% in other countries combined).
Time since last colonoscopy to CRC and survival
The mean time from last colonoscopy to CRC did not
differ between the Finnish and non-Finnish series irre-
spective of the interval between colonoscopies. It was
32.7 (SD 13.6) months for the Finnish series and 31.0
(SD 23.4) months for the non-Finnish series (p > 0.05).
Times since last colonoscopy to CRC in the two series
by 6 months periods are shown in Table 5. Of note, the
rates of interval cancers occurring before the next
planned 2-yearly or 3-yearly colonoscopy were similar in
both series at 56.9% and 50% in the Finnish and the
others respectively (Table 5).
Moreover, there were no differences in the survival of
CRC in MLH1 carriers in the two series. Five- and ten-year
overall survival after CRC was 90% (95% confidence interval:
78-96%) and 88% (75-95%), respectively, in the Finnish
series compared to 96% (85-99%) and 91% (78-97%) in the
1-2-year interval series (p > 0.05). There were not enough
deaths for meaningful stratification by time since last colon-
oscopy with respect to survival. Finally, there were no differ-
ences in survival of extracolonic cancers. Five- and ten-year
survival after extra-colonic cancer was 79% (64-89%) and
79% (64-89%), respectively, in the Finnish series compared
to 82% (68-92%) and 82% (69-92%) in the 1-2-year interval
series (p > 0.05).
Table 3 Baseline characteristics of the study population
All subjects 3-year interval
(Finnish)
1-2-year interval
(non-Finnish)
Observation years 7928 4625 3299
Number of subjects 944 505 439
Gender Male 430 246 (48.7%) 184 (41.9%)
Female 514 259 (51.3%) 255 (58.1%)
Age at inclusion (Mean, SD) 35.5 (11.7) 35.2 (12.1) 36.1 (11.0)
Follow-up time (Mean, SD) 8.4 (5.7) 9.2 (5.9) 7.5 (5.2)
SD standard deviation
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Discussion
This study showed that the high incidence of CRC ob-
served in our combined international series of
path_MLH1 carriers was not caused by a higher inci-
dence in the Finnish series compared to the others. In
contrast to what we expected, the CRC incidence in the
Finnish series was lower than in the others, but not sig-
nificantly so.
First, we considered the possibility that the trend
towards a lower CRC incidence in the Finnish series
could reflect the lower population incidence of CRC in
Finland. In fact, the observed ratio of cumulative risk for
CRC at 70 years showed a similar pattern in the Finnish
and non-Finnish series. Disease expression differences
between Finnish and non-Finnish path_MLH1 carriers
could reflect population-specific environmental and
behavioural factors or a lower penetrance of the Finnish
founder path_MLH1 variants compared to other
path_MLH1 variants but this study shows that these
factors cannot have a major impact on the observed high
cumulative risk of CRC in path_MLH1 carriers in the
total PLSD cohort of path_MLH1 patients.
Secondly, we examined whether or not the Finnish
patients were actually colonoscoped less frequently than
the others. We found that the time between last colon-
oscopy and CRC was similar for both series irrespective
of the recommendations in place. Also, it was evident
that a proportion of CRCs in both series could be classi-
fied as interval cancers (Table 5). In particular, the rates
of interval cancers that occurred before the planned next
2-yearly or 3-yearly colonoscopy were 56.9% and 50% in
the Finnish series and the others, respectively (Table 5).
While the organizational aspects of surveillance at the
non-Finnish centers were heterogenous and details that
might impact our observations were not readily avail-
able, the organization of surveillance in the Finnish
series displays two key features that are critical for the
interpretation of our findings: there are special and dedi-
cated booking and call back systems in place to follow
all identified LS carriers and the reported adherence to
Table 4 Cumulative incidences from 25 years of age and 95% confidence intervals for colorectal cancer and extra-colonic cancer
3-year interval (Finnish) 1-2-year interval (non-Finnish)
Current age Age stop Obs years #Ca Cumulative
incidence (%)
95% CI Obs years #Ca Cumulative
incidence (%)
95% CI
Colorectal cancer
All
25 40 1982 19 12.9 [7.4–18.3] 1299 17 16.4 [9.2–23.7]
25 50 3301 40 25.4 [18.6–32.3] 2424 36 30.0 [21.7–38.3]
25 60 4070 47 31.7 [24.0–39.4] 2935 48 44.9 [34.6–55.2]
25 70 4330 51 39.2 [29.4–48.9] 3094 50 53.8 [39.6–68.0]
Male
25 40 1026 12 15.7 [7.5–23.9] 610 9 18.5 [7.2–29.7]
25 50 1682 25 30.8 [20.7–40.9] 1110 21 37.0 [24.3–49.8]
25 60 2075 29 36.9 [26.1–47.7] 1288 28 57.8 [41.5–74.0]
25 70 2189 30 41.1 [28.2–54.0] 1365 28 57.8 [41.5–74.0]
Female
25 40 956 7 9.6 [2.8–16.4] 689 8 14.8 [5.3–24.4]
25 50 1623 15 19.4 [10.6–28.3] 1314 15 24.1 [13.4–34.8]
25 60 2010 18 26.2 [15.2–37.2] 1646 20 35.2 [22.0–48.3]
25 70 2156 21 36.4 [22.1–50.6] 1729 22 55.3 [30.5–80.0]
Extra-colonic cancer
All
25 40 1982 4 2.7 [0.1–5.3] 1299 3 2.9 [0.0–6.1]
25 50 3301 24 16.9 [10.7–23.2] 2424 22 17.8 [11.0–24.6]
25 60 4070 39 32.2 [23.5–40.9] 2934 35 35.3 [24.8–45.7]
25 70 4330 42 39.7 [28.2–51.2] 3094 41 57.2 [41.0–73.5]
Obs years observation years at age group
#Ca number of cancers during observation
CI confidence interval
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colonoscopy intervals has been consistently very high
throughout the years [4, 8]. Thus, in the Finnish series
non-compliance/adherence with local surveillance
guidelines cannot explain the occurrence of all cancers
and the pattern of time from last colonoscopy to CRC
suggests that only a limited proportion of CRCs would
have been prevented by reducing the interval from 3 to
2 years.
Our study has a number of strengths including: (i) a
large number of observation years; (ii) a focus on
path_MLH1 carriers showing a high cumulative risk
thereby avoiding mixing of carriers of path_MMR vari-
ants in different MMR genes and (iii) the robustness of
the dataset collated based upon prospectively observed
outcomes. On the other hand, several limitations need
to be highlighted: (i) in spite of the number of observa-
tion years included our sample size is still limited. Sto-
chastic variation cannot be completely ruled out and our
observations do not exclude a significant impact of dif-
ferences in population prevalence of CRC on LS expres-
sivity; and (ii) only a detailed analysis of the interval,
quality and reported findings of the colonoscopies will
allow a refined assessment of the impact of this con-
founder. However, such an analysis will not change the
critical observation that time between colonoscopy and
CRC is essentially the same in both series.
The prospective health outcome observations pre-
sented here challenge the dogma that the performance
of very frequent colonoscopies, many of them performed
in expert centers, has a strong primary preventive effect
on CRC incidence in LS. It is notable that despite sur-
veillance, the expert centers with good recall systems in
place that have contributed their data to this study have
not succeeded in preventing CRC as has been achieved
in non-LS familial CRC [20]. Consequently, our observa-
tions set the foundations for a more detailed analysis of
the determinants of this lack of success. In this regard,
there is biological evidence that CRC in LS may arise
directly without a precursor polyp although the relative
contribution of this distinct natural history to the totality
of CRCs observed is a matter of controversy [21–24].
Thus, it is possible that even colonoscopies achieving
the best quality standards would not be able to prevent
all CRCs in LS.
Fig. 1 a Calculated cumulative incidence for colorectal cancer in the
3-year and non-Finnish series. Fin = Finnish series (blue line).
Oth = non-Finnish series (green line). b Calculated cumulative
incidence for extra-colonic cancer in the 3-year and non-Finnish
series. Fin = Finnish series (blue line). Oth = non-Finnish series (green
line). c Calculated cumulative incidence for colorectal cancer by
gender in the 3-year and non-Finnish series. Fin_M = Finnish series,
males (blue line). Fin_F = Finnish series, females (red line).
Oth_M = non-Finnish series, males (green line). Oth_F = non-Finnish
series, females (orange line)
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Whether shorter colonoscopy interval could result in
lower CRC stage needs to be addressed in future studies
with cancer stage included. We are in the process of
expanding our database in this regard.
Conclusions
In summary, we tested whether or not the high inci-
dence of CRC in path_MLH1 carriers observed in our
previous reports was caused by a distinct high incidence
in the Finnish series in which 3-yearly colonoscopy was
recommended. In the present report we show that the
cumulative risk of CRC is high for path_MLH1 carriers
undergoing colonoscopic surveillance irrespective of the
specific characteristics of their country of origin and the
associated factors that may have an impact on the ex-
pression of the disease. The contribution of more obser-
vation years from countries with different population
CRC incidences will be needed to formally test the hy-
pothesis that population CRC incidence correlates with
LS expression. The lack of a difference in the time be-
tween last colonoscopy and CRC in the two series inves-
tigated in this study challenges current beliefs regarding
colonoscopy intervals in LS surveillance. Our findings
mandate a detailed study that will eventually inform pol-
icy makers. Finally, in view of the excellent 10-year over-
all survival in the Finnish and non-Finnish series we
remain strong advocates of current surveillance practices
for those with LS pending studies that will inform new
recommendations on the best surveillance interval.
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